Curium bought Lantheus for eight billion dollars. That's billion with a B. The same amount of money that could solve actual problems just got spent on a radiopharmaceutical company most people couldn't spell without autocorrect.
Radiopharmaceuticals. Drugs with radioactive isotopes attached. The kind of thing that sounds important until you remember these two companies combined probably employ fewer people than a mid-sized Costco. But sure, eight billion sounds right.
Retail traders are frantically googling both companies right now. They missed the run-up. They'll chase it anyway. Some guy named Brett with $4,700 in his Robinhood account is currently watching a YouTube video titled "LANTHEUS MERGER EXPLAINED" uploaded sixteen minutes ago by a teenager with a ring light.
The deal is worth "up to" eight billion. Love that phrase. Up to. Could be seven billion. Could be five. Could be a firm handshake and a Panera gift card depending on how the earnout metrics shake out. But eight billion makes a better headline so that's the number everyone will remember when this thing inevitably gets written down in eighteen months.
Curium's executives will spend the next six weeks on a roadshow explaining synergies. Lantheus shareholders will get their payout and immediately start browsing Zillow for houses they can't afford. The merger will close in nine months after regulatory approval from agencies that definitely understand radiopharmaceuticals and aren't just rubber-stamping this because they're understaffed.
Chart patterns predicted none of this. Technical analysis saw nothing. Your trendlines meant nothing. Your Fibonacci retracements were as useful as a map of Narnia. But don't worry, I'm sure that head and shoulders pattern you spotted last week on a company you can't pronounce will totally work out.
Photo by on Unsplash
Leave a Comment